Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Truist CEO Michael P. Lyons buys 21,000 common shares worth $1,015,576.80

Truist CEO Michael P. Lyons buys 21,000 common shares worth $1,015,576.80

BitgetBitget2026/09/18 11:53
  • Truist President and CEO Michael P. Lyons bought 21,000 common shares at a weighted-average price of $48.36.
  • His directly held common stock position rose to 21,000 shares.
  • Lyons also reported 351,941 restricted stock units linked to Truist common stock.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Truist Financial Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001534574-26-000016), on September 18, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21